Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares saw an uptick in trading volume on Friday . 351,876 shares changed hands during mid-day trading, an increase of 87% from the previous session’s volume of 188,289 shares.The stock last traded at $2.83 and had previously closed at $2.98.

Separately, Maxim Group dropped their price objective on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, July 21st.

The firm’s market capitalization is $42.44 million. The firm’s 50-day moving average price is $3.00 and its 200 day moving average price is $5.49.

In other Adamis Pharmaceuticals Corp. news, SVP David J. Marguglio sold 4,000 shares of the company’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $8.08, for a total value of $32,320.00. Following the transaction, the senior vice president now directly owns 102,227 shares in the company, valued at approximately $825,994.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP David J. Marguglio sold 4,860 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $10.00, for a total transaction of $48,600.00. Following the completion of the transaction, the senior vice president now owns 106,227 shares in the company, valued at $1,062,270. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.